Start Date
January 31, 2011
Primary Completion Date
December 31, 2017
Nimotuzumab
Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
Cisplatin
Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
Brachytherapy
"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.~Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
Cisplatin
Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
Radiation Therapy
"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.~Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.~Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.~28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
Caism - Unicamp, Campinas
Centro de Pesquisas Clínicas da Fundação Amaral Carvalho, Jaú
Centro de Pesquisa Clínica da Liga Norte Riograndense contra o Câncer, Natal
Hospital de Caridade de Ijui - ONCOSITE Centro de Pesquisa Clínica em Oncologia, Ijuí
Hospital Santa Rita - Núcleo de Novos Tratamentos em Câncer, Porto Alegre
ICESP, São Paulo
Hospital Santa Marcelina, São Paulo
Lead Sponsor
Eurofarma Laboratorios S.A.
INDUSTRY